Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 3

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 3
---
 to 1.0%       
 of the initial public offering price payable to the underwriters. We refer you to “Underwriting” 
 beginning on page 136 for additional information regarding underwriters’ compensation            |

We have granted a 45-day option to the representative
of the underwriters to purchase up to 136,364 additional Ordinary Shares solely to cover over-allotments, if any.

The underwriters expect to deliver the Ordinary
Shares on or about , 2025.

<div align='center'>ThinkEquity

The date of this prospectus is ,
2025.

Regenerative medicine company : D eveloping GelrinC® for knee cartilage injuries. Ready - to - use hydrogel : O ffering cost - effective, sustained pain relief and improved function , and better tissue repair Phase II success : 100% greater KOOS * and VAS ** improvement vs. microfracture. Approved : CE mark in Europe FDA pivotal trial : 47 of 80 patients already treated and followed up in the U.S. and Europe . Unique : T here is currently no approved off - the - shelf product in the US for the cartilage repair market. Broader potential : T reats osteoarthritis and other cartilage injuries, supported by animal studies. *KOOS Score: Measures knee pain, symptoms, function, and quality of life, **VAS Score: Rates pain intensity on a 0 – 10 scale.

GelrinC® Procedure Stelar delivery device membrane covers cartilage lesion. Using a syringe GelrinC® is introduced into the lesion. Upon filling of the lesion, UV beam cures GelrinC® into a soft rubbery implant. As GelrinC® implant recedes and resorbs, the cartilage lesion rim creates aggregates and new cartilage tissue fills up the void created by the retreating implant. Within 2 - 3 weeks, pain is significantly reduced, and functionality returns, the GelrinC® implant is resorbed in 6 - 9 months. GelrinC has not been approved by the United States Food and Drug Administration (FDA). Until such approval is obtained, GelrinC may not be sold in the United States. Furthermore, the Company cannot guarantee that GelrinC will be approved by the FDA.

TABLE OF CONTENTS</div>

| PROSPECTUS                                                               
 SUMMARY                                                                  |   1 |
| THE                                                                      
 OFFERING                                                                 |  11 |
| SUMMARY                                                                  
 FINANC